Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Convertible Debt (2019 - 2023)

Ocular Therapeutix has reported Convertible Debt over the past 5 years, most recently at $9.1 million for Q4 2023.

  • Quarterly results put Convertible Debt at $9.1 million for Q4 2023, down 68.21% from a year ago — trailing twelve months through Dec 2023 was $9.1 million (down 68.21% YoY), and the annual figure for FY2023 was $9.1 million, down 68.21%.
  • Convertible Debt for Q4 2023 was $9.1 million at Ocular Therapeutix, up from $8.8 million in the prior quarter.
  • Over the last five years, Convertible Debt for OCUL hit a ceiling of $30.0 million in Q2 2023 and a floor of $8.8 million in Q3 2023.
  • Median Convertible Debt over the past 5 years was $25.3 million (2020), compared with a mean of $24.3 million.
  • Biggest five-year swings in Convertible Debt: grew 10.27% in 2020 and later plummeted 68.87% in 2023.
  • Ocular Therapeutix's Convertible Debt stood at $24.3 million in 2019, then grew by 0.01% to $24.3 million in 2020, then increased by 8.75% to $26.4 million in 2021, then rose by 8.75% to $28.7 million in 2022, then tumbled by 68.21% to $9.1 million in 2023.
  • The last three reported values for Convertible Debt were $9.1 million (Q4 2023), $8.8 million (Q3 2023), and $30.0 million (Q2 2023) per Business Quant data.